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QUANTIFICATION OF MICROVESSEL DENSITY IN BREAST 
CARCINOMAS BASED ON IMMUNOHISTOCHEMISTRY” 
Abstract: 
Breast cancer is the most frequent neoplasm causing death in women 
between 35-55 years of age. Angiogenesis is of key importance in the process of 
tumor progression in a number of tumor types including breast cancer. This is a 
both retrospective and prospective study which included fifty breast cancer 
cases . Angiogenesis was estimated by determining micro vessel counting after 
immune staining the paraffin embedded tissue sections using anti-cd34 
antibody. The study is designed  to compare MVD in different tumor stage, 
grade and age group. Age of the patients ranged from 35 to 85 years with a 
mean age of 52.58 years. Majority showed (40%) more than 84 vessels count in 
1 mm2 field area . Micro vascular density positively correlated lymph nodes 
involved by the tumor and grade of the tumour . In the future, antibodies 
specific to proliferating endothelium, together with the development of 
automated image analysis may improve the accuracy and value of measuring 
angiogenesis-induced microvessel density. 
 Key words: Breast Carcinoma, MVD, Cd- 34, Angiogenesis. 
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INTRODUCTION 
Breast cancer is one of the most common carcinoma among women in 
India, which accounted for 25 to 30 percent of all cancer in woman
(1)
. Breast 
cancer is the second most common cancer with an estimated 115,251 new 
diagnoses
(2)
 and the second most common cause of cancer related deaths 
with 53,592 breast cancer deaths in 2008
(2)
. The incidence of breast cancer 
increases with age. The incidence of female breast cancer is increasing 
between the age group of 35 to 50 years worldwide
3.
 Invasive ductal 
carcinoma comprises the largest group of malignancy which constitutes 
about 65% - 80% of all breast carcinomas
4.
 
Though there is an increase in breast cancer incidence, breast cancer 
mortality is decreasing in the last 20 years 
(4). 
This is mainly caused by both 
the introduction of breast cancer screening and use of adjuvant systemic 
chemotherapy. Breast are made up of specialized epithelium and stroma 
which may give rise to both benign and malignant neoplasm. 
Patients who are at high risk can be identified based on clinical and 
pathological prognostic factors, such as age, menopausal status, size of the 
tumour, grade of the tumour, lymph node status and hormonal receptor 
status.               
In addition to this there are certain predictive factors like, 
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1. Estrogen receptor and progesterone receptor. 
2. HER2/neu amplification : 
HER2 /neu over expression is associated with poor prognosis. But the 
drug transtuzumab can be targeted against this oncoprotein. 
3. Proliferative markers like Ki-67 
4. Angiogenesis 
 One of the emerging predictive and prognostic factor in breast 
carcinoma is tumour induced angiogenesis. Angiogenes is defined as process 
of formation of new blood vessels from the endothelium of the already pre-
existing vasculature. 
It is important in growth, progression and spread of the tumour.
. 
So, 
tumour microvessels are necessary for sufficient supply of nutrients and 
oxygen and removal of waste metabolites from tumour cells.  
In normal life, angiogenesis play a vital role in reproduction, 
embryogenesis, menstruation, and wound healing and repair. Its importance 
in solid tumours was first recognized by Folkman et al in 1971
(5)
, he 
suggested that the growth of tumours was depends on angiogenesis. Micro 
vascular density is considered to be a hallmark of the angiogenesis.             
The first study to examine intratumoral microvesseldensity (IMD) was 
carried out by Weidner and colleagues in 1991with immunohistochemistry. 
They used factor Vlll antigen as an endothelial marker in a series of breast 
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cancers 
(5). 
Since this initial work many antibodies including those against 
CD31 & CD34has been used to assess MVD
6
. 
It has been emphasized that high micro vessels density in growing 
tumors closely associated with increasing number of tumor cells fell into the 
blood stream. In recent years, it has been proposed that quantification of 
intratumoral microvessel density by immunostaining for endothelial cell 
markers, such as CD34, CD31, von Willebrand factor, may be a useful 
prognostic factor in breast carcinomas.  
So our present study was undertaken to asses and correlate the 
microvessel density in breast carcinomas with different clinicopathological 
factors and to ascertain the correlation of tumor angiogenesis with 
metastasis. 
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Aim of the study 
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AIMS AND OBJECTIVES    
1. To quantify and grade the microvessel density in breast carcinomas with 
immunohistochemistry. 
2. To asses and correlate the microvessel density in breast carcinomas with 
different clinicopathological entities with immunohistochemistry. 
3.  To ascertain the correlation of tumor angiogenesis with metastasis. 
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REVIEW OF LITERATURE 
HISTORY 
Breast cancer was known but uncommon until the 19th century, in the 
year 1882 the first mastectomy for breast carcinoma was done by William 
stewart halsted. 
(9)
. The procedure involved excising both breasts, lymph 
nodes, and the pectoralis muscles. Thereafter, the arrival of the Halsted 
radical mastectomy increased the survival rate by 50%. 
Breast cancer staging systems was introduced in the 1920s and 
1930s.
(10)
In 1926, first case-controlled study on breast cancer epidemiology 
was done by Janet Lane-Claypon 
(11)
,who was analysed the first 
epidemiology study on fertility and breast cancer risk.
 
The results from the Nurses Health Study (1995) and the reports of 
the Women's Health Initiative trial (2002) showed that the hormone 
replacement therapy could increase the incidence of breast cancer
(12)
.
. 
 
In 1945, Algire and Chalkley 
[14]
 were the first to determined that 
tumor growth is very closely related to the formation of an new 
microvessels. 
In 1991, the first study to estimate the intratumoral microvessel 
density immunohistochemically was performed by Weidner and colleagues 
(13)
. Theyused factor Vlll related antigen as an endothelial marker in a group 
of breast carcinomas. 
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ANATOMY 
DEVELOPMENT OF BREAST:    
The mammary glands develops from the ectodermal mammary ridges 
at the 5
th
 week of intrauterine life. Bilaterally, they appears as a thickened 
line and it extends on the ventral surface of the fetus from the axillary to mid 
thigh. Around 7
th
 week in utero major part of mammary ridge disappear.But 
some portion of it persist in the 4
th
 or 5
th
 intercostals space called the primary 
mammary buds. 
  Primary buds of ectoderm starts invading into the underlying 
developing stroma.By 10- 12th week of gestation, the primary mammary 
buds branches to form secondary buds, subsequently it forms the mammary 
lobules. 
 In 5
th
 month of fetal development, the ectodermal penetration 
produces 15 –20 radial ingrowths branching into the developing breast. 
Small lumen will develop within the mammary buds which latter forms the 
developing lactiferous ducts and the branches of lactiferous duct.  
The lactiferous ducts converge to open into a mammary pit, which 
then converted into nipple during infancy. There is no discernible variation 
between the male and female breast tissues from the time of conception until 
puberty.  
While at puberty females exhibit branching and further lengthening of 
their ducts accompanied by lobular development and proliferation of fibrous 
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stroma and fat tissues reaching their maximum breast development by the 
age of 20 years.  
The menstrual cycle is accompanied by minor variations of the breast 
tissue, but major physiological changes of the breast tissue are seen during 
pregnancy and lactation. There is major regression of the breast tissue during 
menopause which merges with aging associated atrophy of the breast. 
The breast is a modified sweat gland covered by skin and 
subcutaneous tissue and lies over the pectoralis muscle, being separated from 
it by a fascia.  
 
 
 
 
 
 
 
Fig 1 : Anatomy Of Breast 
The functional unit of the organ is the glandular structure arranged 
into lobes which is made up of the following two components:  
1. The terminal duct–lobular unit  
2. The large duct system.  
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The terminal duct- lobular unit is represents the secretory portion of the 
gland which is composed of lobule and the terminal ductule.The breast 
development depends on the close interaction between these specialized 
epithelial and mesenchymal tissues. The large ducts contains only minimal 
amount of specialized stroma. The intralobular stroma envelopes the acini of 
the lobules. It consists of hormone responsive fibroblast-like cells and 
scattered lymphocytes. The stroma appears myxoid. The interlobular stroma 
is made of dense fibrous connective tissue admixed with adipose tissue. 
 BLOOD SUPPLY: 
Breast is supplied by 3 major arteries and their branches: 
• Predominant blood supplied by Internal thoracic artery, which is a 
branch from internal thoracic artery. 
• Branches of the lateral thoracic, superior thoracic and acromiothoracic 
arteries. 
• Lateral branches of posterior intercostal arteries. 
Venous drainage of the breast follows the course of arteries forming 
an anastomotic circle in the subcutaneous tissue beneath the nipple-areolar 
complex. From this the veins run as 
1. Superficial veins draining into internal thoracic vein. 
2. Deep vein draining into internal thoracic, axillary and posterior 
intercostal veins. 
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LYMPHATIC DRAINAGE: 
1. Axillary lymph nodes: Lymphatic drainage is mainly into the anterior 
group of axillary nodes. Posterior, lateral, central and apical groups of 
nodes also receive either directly or indirectly. These important nodes are 
arbitrarily divided into five groups.  
a. The lateral nodes lie posterior to the axillary vein and receive the 
lymph from the upper limb.  
b. The pectoral nodes located at the inferior border of the pectoralis 
minor, drain most of the breast.  
c. The subscapular nodes situated in the posterior axillary fold, drain the    
posterior shoulder.  
d. The central nodes lie near the base of the axilla, drain the lymph from 
the above three groups.  
e. The apical nodes lie medial to the axillary vein and superior to the 
pectoralis minor.The apical nodes receive the lymph from all the other 
groups. 
2. The internal mammary nodes which lies along internal thoracic vessels. 
3. Supraclavicular node, cephalic node, posterior intercostal, 
subdiaphragmatic and subperitoneal lymph plexus Most of the lymphatic 
vessels from the breast, upperlimb and the lymphatic vessels above the 
umbilicus drain into the axillary nodes. 
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Lymphatic vessels of breast: 
1. The superficial lymphatics overlying skin of breast except nipple and 
areola. They pass radially to the surrounding lymph nodes (axillary, 
internal mammary,supraclavicular and cephalic node ) 
2. The deep lymphatics drain the parenchyma, nipple and areola of breast. 
About 75% of lymph drains into axillary nodes, 20% into internal 
mammary nodes and 5% into posterior intercoastal nodes 
NERVE SUPPLY: 
Nerve supply is by anterior and lateral cutaneous branches of 4
th 
and 
6
th
 intercostal nerves. 
HISTOLOGY: 
The keratinizing squamous epithelium of the overlying skin 
invaginates into the orifices of the nipple, then it is converted in to a double 
layered cuboidal epithelium.The entire ductal-lobular unit is lined by two 
cell layers, luminal epithelial cells and surrounded by layer of myoepithelial 
cells. Luminal cells will be columnar or cuboidal depending on their 
function..The entire glandular epithelial system lies on a continuous 
basement membrane. Occasional scattered endocrine cells are also found in 
normal breast. Both the luminal and myoepithelial cells thought to be arise 
from committed stem cells in the terminal duct. 
The nipple area was formed by the lactiferous duct along with the 
sebaceous unit. The epidermis of nipple and areola is similar to that of 
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normal skin but shows increased melanin content in basal layer. It also 
shows occasional clear cells called Toker cells in the basal layer.   
The luminal cells in the lobules are capable of producing milk.The 
contractile myoepithelial cells assist in milk ejection during lactation and 
also produces structural support to lobules.
 
Immunohistoochemically the luminal epithelial cells were positive for 
keratin, EMA, lactalbumin, GCDFP-15. Myoepithelial cells were positive 
for S-100, Smooth Musle Actin,calponin,caldesmon also shows nuclear 
reactivity for p63 
PHYSIOLOGY OF BREAST: 
 
Estrogen and progesterone plays a major role in the development of 
breast. During the first phase of menstrual cycle the lobules are relatively 
inactive. After ovulation, under the control of estrogen and increasing level 
of progesterone, proliferation of cells increases and the number of acini 
increases per lobule. The intralobular stroma will become edematous. During 
menstruation, as the estrogen and progesterone levels begins to fall there will 
be regression of the lobules with disappearance of the stromal edema. 
During pregnancy the breast becomes completely mature and 
functional. There will be a progressive increase in number and size of the 
lobules which are separated by relatively scant stroma.After delivery,                       
the luminal cells start producing colostrum. As the progesterone level drops 
in the next 10 days there will be milk secretion. On cessation of lactation, the 
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epithelial cells undergo apoptosis, the lobules regress and become atrophic. 
However, full regression will not occur. During premenopause, there will be 
involution of the lobules. In elderly females, the lobules may become 
completely atrophic.  
BENIGN EPITHELIAL LESIONS: 
A large number of benign lesions arising from both the ducts and 
lobules have been found in the breast. These include non-proliferative 
changes, proliferative breast lesions and proliferative breast diseases with 
atypia
16-17
. 
NON-PROLIFERATIVE CHANGES: 
This group comprises lesions such as duct ectasia, simple cysts of 
breast, apocrine metaplasia, fibrosis, adenosis etc. of the breast. All these are 
termed as the fibrocystic changes of breast. These lesions contain small 
fragments of normal duct epithelial cells with a background of cyst fluid and 
cyst macrophages along with scattered bare bipolar nuclei
18
.  
CYSTS OF THE BREAST 
Most of the palpable breast swellings are formed by single or multiple 
cysts in the breast. The fibrocystic diseases usually present as cystic 
swellings containing a single layer of cuboidal or flattened epithelial cells. 
At times, a papillary pattern may be found. The lumen of the cysts contain 
fluid composed of desquamated cells and cyst macrophages (large cells with 
vacuolated cytoplasm), also known as foam cells. 
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The cystic fluid also contains various numbers of benign duct 
epithelial cells which are most often poorly preserved. If papillary 
proliferation is seen in the cysts, the epithelial cells will be larger and in 
large numbers. Almost one-third of the cystic swellings are lined by large 
cells called apocrine cells, which are larger with abundant eosinophilic 
granular cytoplasm. 
FIBROCYSTIC DISEASE: 
Fibrocystic disease is one of the most common disorders of the female 
breast. Mature woman are most commonly affected especially during the 
period of pre-menopausal years. It involves all the three (ductal, lobular and 
stromal) elements of the breast. The disorder is also referred as 
fibroadenosis, cystic mammary dysplasia, benign mammary dysplasia, and 
benign cystic mastopathy. The involved ducts are dilated at various levels 
(duct ectasia), which show as cystic swellings containing fluid. The lobular 
ductules undergo hyperplastic proliferation (adenosis) and are surrounded by 
proliferating stroma (fibrosis). 
 In Sclerosing adenosis, a variant of fibroadenosis, the hyperplastic 
ductules are separated into tubules by dense collagenous bands of fibrous 
tissue. The lining epithelium may also be hypertrophied and multiplied 
(epitheliosis).They are usually diagnosed by the honey comb pattern of the 
sheets of benign duct epithelial cells and the presence of benign apocrine 
cells and foam cells in the background of scattered naked bipolar nuclei
16
. In 
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cases with marked duct ectasia, necrosis is seen and the foamy macrophages 
show inspissated secretions containing dark-staining nuclei and a “dirty” 
appearing cytoplasm
17
. 
The cellular composition of fibrocystic disease may vary.In cases of 
marked fibrosis, the dense collagenous tissue resists aspiration and hence the 
sample will be acellular. If adenosis is predominant, the smear reveals only 
epithelial cells. The cytological diagnosis thereby will be incomplete and 
inadequate. 
 Wellings and Alpers
18
observed that no apocrine metaplasia was seen 
in the patients between the ages of 13 and 19 while this change was found in 
almost half of the patients above 30 years of age.  
PROLIFERATIVE BREAST LESIONS: 
 These are again subdivided into two groups proliferative breast 
diseases without / with atypia. Under the category of proliferative disease 
without atypia comes the moderate to florid epithelial hyperplasia 
(epitheliosis), complex sclerosing lesion (radial scar), papilloma, sclerosing 
adenosis. While under the category of proliferative disease with atypia 
comes the atypical ductal / lobular hyperplasia. 
EPITHELIAL HYPERPLASIA: 
 The ducts and lobules of the breasts are normally lined by the two 
layers of epithelial and myoepithelial cells. When more than two layers of 
cells which may be of either luminal or myoepithelial cell type are seen, it is 
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termed as epithelial hyperplasia. These hyperplastic cells proliferate and 
distend the lobules and ducts leading to the formation of irregular lumens. 
 Cytologically, they are identified by the streaming pattern of 
arrangement of large slightly disorganised sheets of cohesive duct epithelial 
cells with focal crowding and overlapping of the nuclei, associated with mild 
nuclear atypia in a background of bare bipolar nuclei and foamy cells
19
. 
ATYPICAL DUCTAL HYPERPLASIA: 
 Atypical ductal hyperplasia is identical to that of low grade ductal 
carcinoma in situ in various entities like high cellular proliferation etc. Till 
now no single feature has been found with reliability to differentiate between 
them
20
. 
 Cytologically, the smears are highly cellular and present typically in a 
cribriform pattern of large sheets of cohesive mildly atypical epithelial cells 
in a background showing naked bipolar and myoepithelial nuclei, necrotic 
debris and calcium granules. 
DUCT PAPILLOMA: 
 The duct papilloma most commonly affects the main secretory ducts 
and present with a bloody discharge from the nipple. The epithelial lining of 
the affected ducts hypertrophies and projects into the cyst cavity as papillary 
projections which have a dense fibro vascular stromal core lined by 
epithelial cells showing mild nuclear atypia along with macrophages and 
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variable amount of cystic fluid in a background showing sparse naked 
bipolar nuclei
31
. Benign duct papillomas may be single or many in number
21
. 
INVASIVE DUCTAL CARCINOMA: 
In 2
nd
 century A.D Galen opined that “The breast carcinoma exactly 
resembles that of the animal crab”. He also compared the veins that arose 
from the unnatural growth to that of the crab’s legs
23
 Rosen
24
 (1979) 
suggested that invasive ductal carcinoma constituted nearly 75% of the 
deaths due to breast cancer. Currently, the Terminal Duct Lobular Unit 
(TDLU) is considered to be the site of origin for both invasive ductal as well 
as lobular carcinoma. 
Azzopardi
25 
et al also stated that most ductal carcinoma originate from 
the TDLU. Most of the breast malignancies that arise from ductal or lobular 
epithelium are adenocarcinomas. The predominant type among these are 
invasive ductal carcinomas (80%). Invasive ductal carcinoma of No Special 
Type (NST) constitutes the majority of the invasive ductal carcinomas 
(75%)
26,27.
 
 Cytologically, they are highly cellular with neoplastic cells being 
arranged in irregular dyscohesive aggregates or sheets with large 
pleomorphic cells with malignant nuclear features in a background of 
nuclear debris and granular calcium
22
. 
The other types of primary breast carcinoma are as follows:  
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 Lobular carcinoma, mucinous carcinoma, tubular carcinoma, 
medullary carcinoma, papillary carcinoma, clear cell carcinoma, secretory 
carcinoma, adenoid cystic carcinoma and metaplastic carcinoma. 
INVASIVE DUCTAL CARCINOMA 
Invasive ductal carcinoma are tumors in which stromal invasion is 
detectable.Regardless of the presence of in situ component and the relative 
proportion of in situ and invasive component they are included under 
invasive carcinoma.  
Invasive carcinomas can be classified into two major categories- 
ductal and lobular type. Invasive ductal carcinoma comprises 75-85% of 
mammary carcinoma.Invasive ductal carcinoma,not otherwise specified 
comprises majority of duct carcinoma.Other relatively infrequent forms of 
infiltrating ductal carcinoma include tubular,medullary,metaplastic,colloid 
carcinoma etc.,
21
  
CYTOARCHITECTURAL TYPES: 
INVASIVE DUCTAL CARCINOMA, NOS TYPE: 
 IDC,NOS type comprises 75 % of all the cases of breast carcinoma. It 
represents the prototype of all breast carcinomas.
7
The tumor is usually a ill- 
circumscribed firm tumor.It shows a grayish yellow cut surface. The 
trabeculae radiates through the surrounding breast parenchyma in to the 
adjacent fat with a crab like or stellate configuration. 
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Figure 2  -  Gross Appearance Of Invasive Ductal Carcinoma 
In case of larger tumors areas of hemorrhage, necrosis and cystic 
degeneration may be present. In older days the term scirrhous carcinoma has 
been used for tumors with hard consistency. The hard consistency is due to 
presence of large amounts of stroma.
 
 
 
 
 
 
 
 
Fig-3 Microscopic Appearance Of Invasive Ductal Carcinoma 
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The tumor shows various growth pattern like diffuse sheets, 
nests,cords,trabeculae and also as individual cells.Glandular differentiation 
may be well developed to barely detectable. The individual tumor cells are 
usually large and pleomorphic compared to that of classical invasive lobular 
carcinoma.  
The tumor shows prominent nuclei and nucleoli and increased mitotic 
figures. About 60% of the cases shows areas of necrosis.The amount of 
stroma varies from scant to abundant desmoplastic stroma. Elastic tissue are 
present in about 90% of cases. The presence of chalky streaks on gross 
examination is due to the presence of elastosis involving the vessel and duct 
walls.About 60% of the cases show calcification. The interphase between the 
tumor and stroma shows mononuclear cell inflammatory infiltrates.
8 
Studies done by Fisher et al. showed that lymphatic, blood vessel and 
perineural invasion was found in 33%, 5% and 28% of the cases
7a
.
 
The tumor 
cells are positive for low molecular weight keratin (8,18 and 19) and EMA. 
Other sensitive breast related markers are mammoglobin and GCDFP 15.The 
basement membrane components collagen 4 and laminin shows a 
discontinuous linear pattern or it may be totally absent. 
(8) 
 INVASIVE CRIBRIFORM CARCINOMA: 
Invasive cribriform carcinoma is a rare form of breast malignancy. 
  The tumor shows a cribriform appearance similar to that of its 
intraductal counterpart but in addition it shows stromal invasion. Cribriform 
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pattern is often seen in association with tubular formations. Page et al 
proposed that the relative proportion of the two elements determine the term 
to be used.  
 
    
 
 
 
 
 
Fig 4 : Microscopic Appearance Of Invasive Cribriform Carcinoma 
The tumor has an excellent prognosis. 
TUBULAR CARCINOMA: 
Pure tubular carcinoma comprises less than 2% of invasive breast 
cancer. But in mammographic screening 9-19 % of cases can be detected. It 
is easily detectable due to its speculate nature and cellular stroma. 
The gross feature of tubular carcinoma is similar to that IDC, NOS 
type with poorly circumscribed margins and hard consistency. But the size of 
the tumor is usually small with a mean diameter of 1 cm. 
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Fig 5 : Microscopic Appearance Of Tubular Carcinoma. 
The tumor shows haphazard arrangement of glands without any 
organoid configuration. The characteristic feature of tubular carcinoma is 
irregular and angulated contour of the glands.The lining cells show apocrine 
type snouts in the apical cytoplasm.They lack myoepithelial cells and 
basement membrane. The lumina of the glands are open and filled with 
basophilic secretion. It shows a cellular desmoplastic stroma. The tumor is 
cellular with fat invasion in the periphery. Because of the well differentiated 
nature of the glands, scant pleomorphism and absence of necrosis it 
simulates benign conditions like microglandular adenosis,sclerosing 
adenosis and radial scar.
(7-8) 
DCIS can be seen in majority of the cases. The 
in situ component is usually of low grade showing cribriform or papillary 
pattern. 
Tubular pattern can be seen associated with invasive ductal carcinoma, 
NOS type or sometimes with invasive lobular carcinoma.In this instances, 
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the term tubular NOS and tubular mixed can be employed.When the tubular 
pattern is more than 75 %,the tumor shows better prognosis than ductal 
carcinoma NOS type. The term tubular carcinoma can be best employed for 
tumors in which tubular pattern is present for atleast 90 % of the tumor. 
These tumors are associated with favorable prognosis. 
MUCINOUS CARCINOMA: 
Mucinous carcinoma was classified under mucin producing 
carcinoma. Other mucin producing carcinomas are mucinous 
cystadenocarcinoma, columnar cell mucinous carcinoma and signet ring cell 
carcinoma. 
The tumor usually occurs in postmenopausal women. It is also called 
as mucoid, gelatinous or colloid carcinoma.The tumor is well 
circumscribed.Cut surface of the tumour shows a characteristic glistening 
and gelatinous appearance. 
 
 
 
 
 
 
 
Figure-6 Gross Picture Of Mucinous Carcinoma 
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 The tumor cells are arranged usually in small clusters floating in a 
mucinous pool which are surrounded by bands of fibrous septa.The tumor 
cells show little pleomorphism.Mitotic rate is uaually low.The mucin is 
usually extracellular.The mucin may be acid or neutral type.The in situ 
component is usually difficult to recognize. 
Histochemically, the mucins are o-acylated forms of sialomucin. 
Immuohistochemically there is strong MUC2 positivity in 
cytoplasm.Estrogen and progesterone receptors are always positive whereas 
Her 2 neu will be negative. 
    Few studies suggest that mucinous carcinoma can be classified as A 
and B based on the endocrine differentiation. Type A tumors shows 
trabeculae of malignant cells with minimal intracytoplasmic mucin. The cells 
do not show argyrophilia.Type B tumors showas sheets of tumor cells with 
abundant intracytoplasmic mucin. Argyrophilia can be demonstrated in the 
tumor cells. 
   Nodal Metastasis is very low which accounts for 2-4% of node 
metastasis.
(8)
 They are positive for estrogen and progesterone receptors. They 
usually do not show HER2/neu overexpression or p53 accumulation. 
MEDULLARY CARCINOMA: 
The tumor is most common in patients under 50 years of age.The 
tumor is common among carriers of BRCA1 mutation. The tumor is well 
circumscribed, solid and homogenous. 
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  The tumor grows in a diffuse pattern with minimal or absent glandular 
differentiation. The individual tumor cells are large, pleomorphic with large 
nuclei and prominent nucleoli. 
 
 
 
 
 
 
 
 
Figure 7: Microscopic Appearance Of Medullary Carcinoma. 
The cell borders are indistinct which gives the tumor a syncytial 
arrangement.Spindle cell metaplasia, tumor giant cells and necrosis may 
occur.The tumor shows prominent lymphoplasmacytic infiltrate at the 
periphery of the tumor which is an characteristic feature of medullary 
carcinoma. The infiltrate was thought due to the reaction of host tissues to 
the neoplasm. They are usually peripheral T cell type. 
They are positive for CK7, p53. They are negative for hormone 
receptors (ER,PR),Her2/ neu and comes under triple negative phenotype. 
The tumor expresses HLA-DR antigen which could the possible reason for 
the prominent lymphoplasmacytic infiltrate. Though axillary lymph node 
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involvement are common, only few and low axillary group of lymph nodes 
will be involved.The prognosis will be better than IDC, NOS type.
(7-8)
. 
 ATYPICAL MEDULLARY CARCINOMA: 
The tumor shows same growth pattern that of typical medullay 
carcinoma but lacks the classic microscopic features.   
The tumor shows  
 Syncytial growth comprising > 75% of the tumor 
 Atypical features 
 Focal tumor infiltration at the margins 
 Uniform nuclei and rare mitosis 
 Mild to absent lymphoplasmocytic infiltration at the margins. 
 Focal tubule formation.
 (7-8)
 
 
 
INVASIVE PAPILLARY CARCINOMA:  
The tumor is rare and occurs more frequently in the postmenopausal 
women. Most commonly papillary carcinomas present as in situ lesions. The 
invasive component can be papillary or it may show features of IDC, NOS 
type. As the presence of invasion in these tumors are not clearcut, it should 
be applied for cases only with well differentiated true papillary structures. 
When a tumor with papillary pattern is seen, metastatic papillary carcinoma 
from other sites should also be excluded. 
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                    Fig -8 Invasive Papillary Carcinoma 
The tumor may have axillary lymph node metastasis particularly in 
solid variant of papillary carcinoma. Prognosis of the tumor is better 
compared to that of invasive ductal carcinoma, NOS type.
(7-8)
 
INVASIVE MICROPAPILLARY CARCINOMA: 
Invasive miropapillary carcinoma is a distinct rare variant of invasive 
ductal carcinoma. When the micropapillary pattern is found throughout the 
tumor it is referred as pure invasive micropapillary carcinoma. When it is 
present as a part of conventional IDC it is called as mixed invasive 
micropapillary carcinoma.But the criteria to distinguish this two is not clear 
cut. Some authors suggest atleast 50 % of the tumor should be 
micropapillary to call it as pure invasive micropapillary carcinoma. 
The tumor is composed of clusters of cells arranged in micropapillary 
or tubular pattern.The tumor cells are found free floating in clear spaces. 
Fibrovascular core will be absent in the micropapillary clusters. The clusters 
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exhibit a “inside out” arrangement. The apical cells are polarized outside and 
this can be evidenced by MUC 1 staining. 
The nuclear grade of this tumor cells will be high. About half of the 
cases may show psammoma bodies. In situ component seen in these cases is 
usually micropapillary and sometimes cribriform pattern. 
Lymphatic invasion was reported in more than 50 % of the 
cases.Lymph node metastasis usually occur.The tumor have a bad 
prognosis.
(7-8)
 
Estrogen receptor were positive in 72-75 % of cases and 45 % cases 
were positive for progesterone receptor.36 % of the cases show Her 2-neu 
overexpression.   
APOCRINE CARCINOMA: 
  Apocrine carcinoma is very rare comprising 0.5 % of all breast 
carcinoma. The tumor is composed entirely or predominantly of apocrine 
type cells.The tumor cells are large with abundant eosinophilic cytoplasm 
with vesicular nucleus and prominent nucleoli. Glandular differentiation can 
be seen with apocrine snouts. Diagnosis of apocrine carcinoma should only 
be made when the architectural features are those of a malignant tumor. 
Immunohistochemically they are positive for GCDFP-15.Estrogen and 
progesterone receptors will be negative. 
(7-8)
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SECRETORY CARCINOMA: 
    Secretory carcinoma are rare tumors and seen in children. It can also 
occurs in adults. It has a excellent prognosis. The tumors are usually small 
and well circumscribed. 
 
 
 
 
 
 
 
Figure 9:Microscopic Appearance Of Secretory  Carcinoma 
The tumor is composed of tubuloalveolar and papillary structures. The 
lumina contain eosinophilic PAS positive, diastase resistant material. The 
malignant cells have a pale staining vacuolated cytoplasm.Nucleoli may be 
prominent. Mitosis is scanty. 
   There is a strong immunoreactivity for S-100 and a-lactalbumin. 
NEUROENDOCRINE TUMORS: 
Primary neuroendocrine tumors of breast represent tumors which 
shows morphological features similar to neuroendocrine tumors of other 
sites. In these tumors more than 50 % of the cell population express 
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neuroendocrine markers.This group doesnot include invasive carcinoma, 
NOS type which shows focal neuroendocrine differentiation. 
 
 
 
 
 
 
 
Figure 10- Breast Carcinoma With Neuroendocrine Differentiation 
Neuroendocrine tumors of breast include 
• solid neuroendocrine carcinoma 
• atypical carcinoid tumor 
• small cell carcinoma 
• large cell carcinoma   
The clinical presentation is similar to that of invasive ductal 
carcinoma. Bilaterality and multicentricity can occur. 
  Grossly the tumors has no distinctive features. 
   In most of the neuroendocrine tumors, the cells are arranged as solid 
nests or alveolar structures separated by fibrous tissue. The tumor cells are 
usually small in size. In large cell carcinoma, the tumor is composed of large 
clusters of cells with moderate to abundant cytoplasm, vesicular nucleus and 
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high mitotic rate. Minority of the cases show intraductal component and 
mucin secretion. 
    The tumor cells are argyrophilic. Ultrastructurally, they contain dense 
core secretory granules. Immnohistochemically, they are positive for 
chromogranin, synaptophysin and neuron specific enolase. Apart from 
carcinoid tumors many mucinous carcinomas
48
, few in situ and invasive 
lobular carcinoma are also argyrophilic.. Studies done by Upalakalin et al. 
found that among carcinoid tumors 21 % were metastasis from intestine, 
lung
8a
. 
 
Estrogen and progesterone are found positive.
(7-8)
 
METAPLASTIC CARCINOMA: 
Metaplastic carcinoma represents tumor predominantly with cell type 
other than epithelial and glandular component. It includes many categories 
but which overlap with each other. Metaplastic carcinoma is more aggressive 
than invasive ductal carcinoma.Metastasis is usually hematogenous rather 
than lymph node metastasis.
(7-8) 
The tumors are circumscribed, firm to hard in consistency. 
Degenerated cystic areas can be seen in cases with squamous metaplasia. 
Some of the tumors may have infiltrative borders. 
A.Squamous cell carcinoma: 
The tumors are large with cystic spaces filled with keratin. 
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In pure squamous cell carcinoma the central cystic cavity is lined by 
malignant squamous cells. Most cases represent squamous metaplasia. 
   Other two variants which can be seen will be acantholytic squamous 
cell carcinoma and adenosquamous carcinoma. Low grade adenosquamous 
carcinoma is said to have a favourable prognosis whereas acantholytic 
squamous cell carcinoma have a aggressive behavior. 
B.Carcinosarcoma: 
Microscopically the sarcoma like component can be malignant fibrous 
histiocytoma, osteosarcoma, chondrosarcoma, angiosarcoma or a 
combination of various components.When the transition between 
sarcomatous and carcinomatous component is gradual and sharp, it is termed 
carcinosarcoma. 
 
 
 
 
 
 
 
 
Figure 11- Microscopic Appearance Of Metaplastic Carcinoma 
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When the transition to osseous or cartilaginous elements is direct 
without any intervening spindle cell component or osteoclastic giant cells,it 
is called matrix producing carcinoma.  
    Molecular studies suggest that the epithelial and sarcoma like 
components originate from same stem cell. 
   The sarcoma like elements acquire vimentin and other mesenchymal 
features.It is referred to as the phenotypic switch.The cells are occasionally 
positive for epithelial markers. 
PAGETS DISEASE: 
   Pagets disease was originally described by Sir James Paget in 1874. It 
is a crusted lesion of nipple caused by underlying breast carcinoma. About 1-
2% of patients with mammary carcinoma show pagets disease. The 
accompanying breast carcinoma is usually a intraductal carcinoma.It may be 
associated with or without stromal invasion. The epidermis of the nipple 
shows characteristic of Paget's cells in the keratinizing epithelium. The cells 
may be singly scattered in the superficial epidermis. They may also form 
clusters in the basal portions of the epidermis. Individual cells have a pale or 
clear cytoplasm and their nuclei have a prominent nucleoli. 
  Intraductal carcinoma is usually of comedo or solid growth 
pattern.About 10 % of the cases show cribriform or papillary carcinoma and 
40 % the cases show mixed type of in situ carcinoma. 
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   79-100 % the cases are strongly positive for Her 2/neu.The underlying 
insitu lesions are frequently Her2 /neu.
(7-8) 
 
 
 
 
 
 
 
 
 
Figure 12- Pagets Disease Of Nipple 
 
INFLAMMATORY CARCINOMA : 
  The diagnosis of inflammatory carcinoma is essentially based on 
clinical criteria. Clinically, the entire breast is red, warm. The skin shows 
widespread edema which resembles that of mastitis. It has been believed that 
clinical appearance is due to widespread carcinomatosis of dermal lymphatic 
vessels. Skin biopsy is usually performed to reveal dermal lymphatic 
permeation. Histopathological examination of some of the cases show a 
undifferentiated carcinoma. 
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  The prognosis is usually bad. Studies done by Charafe-Jauffret et al. 
found most inflammatory carcinoma are negative for estrogen and positive 
for MIB1,E-Cadherin and Her2 neu.
(7-8)
. 
RISK FACTORS
 
Several risk factors have been established for the development of 
breast carcinoma. The common denominator for most of the factors will be 
strong and prolonged estrogen stimulation in a genetically susceptible 
background.
 
AGE: 
Majority of the breast cancers are detected during the reproductive age 
group.
(28)  
RACE AND ETHNICITY: 
  The incidence is high in northern Europe and North America (91.4 
new cases per 100 000 women/year), intermediate in southern European and 
low in African and asian countries. In the United States due to increased 
mammographic screening there has been a increase in the detection of breast 
carcinoma.
29
 Due to earlier diagnosis and improved therapy the mortality has 
began to fall in some regions like North America, western Europe, and 
Australia.
29
  
FAMILY HISTORY: 
The risk is 2-3 times higher than general population if the first degree 
relative of the women had breast cancer.
30 
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MENSTRUAL HISTORY: 
Early menarche and late menopause is associated with increased risk 
of carcinoma.
30
 
PARITY:  
 There will be a increased risk in case of Nulliparity and late age at first 
child birth. It has been documented that there is a reduced risk of breast 
carcinoma in premenopausal women who have lactated.
29
 
HORMONE REPLACEMENT THERAPY: 
 Many studies showed that there is an increased risk of breast 
carcinoma in women under hormone replacement therapy than women using 
estrogen alone. 
(32)
 
RADIATION: 
 An increased risk of breast cancer has been documented on exposure 
to ionizing radiation particularly when the exposure is at the time of breast 
development.
(36) 
PRECANCEROUS LESION: 
Complex fibroadenoma,florid hyperplasia without atypia,solitary 
papilloma without atypical hyperplasia, sclerosing adenosis are associated 
with a risk of 1.5-2 times than that of general population.Atypical ductal 
hyperplasia and atypical lobular hyperplasia are associated with a risk of 4.0-
5.0 than that of general population.
33 
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BREAST DENSITY : 
Breast density solely and strongly contributes to the risk of breast 
cancer
(32)
.  
GENETIC PREDISPOSITION:                        
 About 5-10 % of breast cancers are familial.
33
 In various studies it has 
been reported that the risk of developing breast carcinoma due to BRCA1 
mutation will be 56% to 90%.Women carrying BRCA2 mutation have a risk 
of 37% to 84%.BRCA1 mutation may account for about 45% of cases of 
hereditary breast carcinoma and they are usually of poorly differentiated type 
with high proliferative rate.
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MODIFIABLE
 
RISK FACTORS
 
BODY MASS INDEX(diet)
 
Western diet (High caloric diet rich in proteins and animal 
fat),obesity
30
,,sedentary lifestyle are associated with increased risk of breast 
carcinoma
34
.  
ALCOHOL CONSUMPTION: 
Increased alcohol consumption associated with increased risk of breast 
carcinomas
30,35
.
 
PROGNOSTIC AND PREDICTIVE FACTORS: 
A predictive factor is the one that gives information about the 
response of a tumour to a specific treatment.  
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A prognostic factor gives information about the recurrence risk of the 
tumour in the absence of the adjuvant therapy, that is a prognostic factor is a 
factor that helps to predict the natural history of a tumour.  
Many prognostic and predictive factors help in the process of 
estimation of risk for recurrence and in selection of additional therapies. 
 AGE : 
Women less than 50 years have the best prognosis. Older patients 
have a higher rate of recurrence and distant metastasis
7
. 
PREGNANCY:  
Carcinoma breast manifesting during pregnancy may enhance tumour 
angiogenesis, over expression of Her 2 neu, and low expression of hormone 
receptors. The tumors are generally aggressive in these cases.
7 
GENE:
 
Studies showed that BRCA1 mutation carriers have a low survival 
rate. 
SKIN AND NIPPLE INVASION: 
Invasion of overlying skin is associated with decreased survival rate. 
Nipple involvement is associated with high incidence of axillary node 
metastasis   
PRESENCE OR ABSENCE OF INVASION: 
The single most important prognostic determinator is the presence of 
invasive component. In case of a tumor with both an invasive and in situ 
component,the invasive component is proportional to the nodal 
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metastasis.The in situ component is directly related to the incidence of 
multicentricity and indirectly with occult metastasis.
 
HISTOLOGICAL TYPE OF TUMOUR: 
Variants of invasive ductal carcinoma like tubular carcinoma, 
cribriform carcinoma, medullary carcinoma, papillary carcinoma, pure 
mucinous carcinoma and secretoty carcinoma have a more favorable 
prognosis than Invasive ductal carcinoma,NOS type. Signet ring cell 
carcinoma have a bad prognosis. 
NECROSIS: 
Spontaneous tumor necrosis is associated with tumors showing high 
histological grade and increased incidence of lymph node metastases.
7 
LYMPHOVASCULAR INVASION: 
Lymphatic emboli within the breast is associated with higher tumor 
recurrence. 
58
Vascular emboli is highly correlated with tumor size, tumor 
type, histological grade, lymph status and have a poor prognosis.
 
LYMPH NODE STATUS AND TUMOUR SIZE: 
For a woman with operable breast cancer the presence of lymph node 
metastases is the strongest prognostic factor 
[37].
 The pN staging is a 
qualitative parameter. 
The prognostic value of lymphnode status can be increased by 
counting the number of lymph nodes. This has been shown in an study done 
on more than 24,000 women in American population 
[38].
 A minium of 10 
lymphnodes should be examined to correctly establish pN status 
[39].
 The 
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quality of the procedure by counting the number of examined lymph nodes 
depends on both the surgeon and the pathologist 
[40]. 
 
The tumour size is also another useful prognostic factor and can be 
obtained in almost all cases. Thus, recurrence risk has been correlated with 
tumour size 
[41, 42,]. 
TUMOUR GRADE: 
The current grading system in use was first proposed by Bloom and 
Richardson
[43]
 and thereafter it was reclassified by Elston and Ellis 
[44].
 
HISTOLOGICAL GRADING SYSTEM: 
Tumor grade is describing the tumor on the basis of how much 
abnormal the tumor cells and the tumor tissue look under a microscope. 
Bloom and Richardson histological
(43)
 grading method is most commonly 
used for grading the breast cancer. This method is very simple and gives 
very good prognostic implications. This system grades breast cancer into 
three types on the basis of the following three criteria:  
i. measurement of tubular differentiation 
ii. nuclear pleomorphism, and  
TNM N0 Stage 1 No node involvement 
TNM N1 Stage 2 Upto 3 axillary/single internal mammary node 
involved 
TNM N2 Stage 3 4 or more axillary node involved 
TNM N3 Stage 3 >10 axillary node involved. 
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iii. proliferative index. 
TABLE -1: MODIFIED BLOOM AND RICHARDSON GRADING   
SYSTEM 
PARAMETER CRITERIA SCORE 
Tubule formation >75% 1 
 10-75% 2 
 <10% 3 
Nuclear pleomorphism Small and uniform 1 
 Moderate variation 2 
 Marked variation 3 
Mitotic count/hpf 0-5 1 
 6-10 2 
 10-15 3 
TABLE-2: BLOOM RICHARDSON GRADING SYSTEM 
GRADES SCORE 
Grade -1(well differentiated) 3-5 
Grade-2(moderately 
differentiated) 
6-7 
Grade-3(poorly differentiated) 8-9 
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Added score Tumour grade Degree of differentiation  
• 3-5 Grade I Well differentiated 
• 6-7 Grade II Moderately differentiated 
• 8-9 Grade III Poorly differentiated 
According to Elston and Ellis tumour grade is a well developed 
prognostic indicator for overall survival of breast cancer patients 
[44, 45].
 The 
estimation of histologic grade is simple and cheap, so that it can be done in 
almost all woman with breast carcinoma. One of the disadvantages is that the 
estimation of histologic grade usually varies among the observers.  
Boiesen and co-writers
46
 were performed histologic grading on ninty 
three breast carcinomas patients in seven pathologic departments, results 
showed an mean kappa value of 0 and 54, which indicates a moderate level 
of reproducibility. 
 ESTROGEN- AND PROGESTERONE RECEPTOR STATUS : 
Studies found that a vast majority of breast cancer tumours expressed 
oestrogen receptors and progesterone receptors. The first study on the 
prognostic importance of estrogen receptor was done almost 20 years ago 
[49].
 
However, estrogen receptor and progesterone receptor are not strong 
prognostic indicators with longer follow-up time, though women with 
positive receptor breast carcinomas have a good prognosis compared to the 
receptor negative breast cancer
[50]
. 
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Only in the late 1970ies, the value of estrogen receptor and 
progesterone receptor as predictive factors was demonstrated 
[51]
. 
Tumours with both estrogen and progesterone receptor positive are 
benefit more from hormonal therapy than those who have either estrogen or 
progesterone receptors 
[52]
. 
  Approximately 50-60% of women with positive receptor late stage 
breast cancer will have better response from hormonal therapy than receptor 
negative women 
[53]
. 
Currently, the biochemical analyses of estrogen receptor and 
progesterone receptor are largely replaced by immunohistochemistry. 
Immunohistochemistry gives superior prognostic information and it is more 
valuable for small tumours 
[53-54]
. 
DNA CONTENT AND CELL PROLIFERATION MEASUREMENT: 
DNA-PLOIDY: 
DNA-ploidy is a measure of the deoxy ribonucleic acid content within 
the nucleus of somatic and germ cells. The normal cells are either diploid or 
euploid. 
  Measurement of DNA content within tumour cells has been applied to 
evaluation of number of tumour types. Bagwell et al showed that ploidy 
analysis may be useful prognostic test for node negative breast carcinoma
47
. 
Flow cytometry is the most common method used to measure the 
DNA content in cell nuclei. 
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 Due to genetic instability most of the cancerous cells have a abnormal 
amount of DNA which may greater or lesser than that of actual amount of 
DNA.It is usually associated with a worse prognosis and this is called 
aneuploidy 
[47].
 
S-PHASE FRACTION (SPF): 
The S-phase of DNA-synthesis takes place before cell division and 
hence it measures the proliferative activity of the cell. The number of cells in 
S-phase can be estimated by means of flow cytometry 
[48].
. Most of the 
studies revealed that high SPF associates with greater recurrence risk of 
breast cancer, and is considered as a prognostic factor. 
 NEW PROGNOSTIC AND PREDICTIVE FACTORS: 
The recently recognised prognostic and predictive markers provides 
more reliable information on prognosis and treatment selection.  
A prognostic factor provides information on the outcome, irrespective 
of the different therapies employed. Whereas, a predictive factor gives 
valuable information on the likely benefit from a particular treatment. 
So far, the sex-hormone receptor status is the only well established 
predictive factor useful in the management of patients with breast carcinoma. 
Therefore,an increase in need for other markers, especially prognostic- 
and predictive factors employing at the individual level. 
Indeed, many studies were conducted to identify different risk groups 
based on certain prognostic factors 
[55]. 
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In recent years, there are three emerging predictive and prognostic 
factors of special interest as follows, 
• c-erbB-2 gene, 
• p53 gene and 
• angiogenesis. 
One of the markers, c-erbB-2 oncogene is a routinely used predictive 
factor, while p53 tumour suppressor gene and angiogenesis in the future may 
be of value in management of breast cancer. 
c-erbB-2: 
c-erbB-2 is an oncogene situated on the q arm of 17
th
 chromosome
 [55].
, 
which encodes a tyrosine growth factor receptor belongs to EGFR(epidermal 
growth factor receptor). 
[56].
 
In a Swedish population based study showed that the prevalence of 
overexpression of c-erbB-2 was 19% among the breast cancer patients
.[57].
  
Most of the studies revealed that overexpression of c- erB-2 gene has been 
associated with bad prognosis
(57,58),
,though some studies have found that 
there is a strong association between over expression of c-erB-2 and reduced 
sensitivity to chemotherapy and tamoxifen
.(60-61) 
 
As a result, evaluation of c-erbB-2 status with immunohistochemistry 
on tumour sections has become a routine analysis for women with breast 
cancer. 
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p53: 
p53 is a tumour 48uppressor gene situated on the p arm of 17
th
 
chromosome 
[59,62].
 Because of its crucial role in control of cell cycle, 
apoptosis and DNA repair mechanism, p53 is rightly known as “the 
policeman of the genome” 
[59].
 
P53 Mutation is identified nearly 20-25% of breast carcinomas
 63. 
 
The commonest method of determining p53 protein is 
immunohistochemistry on tumour sections. This method detects 
accumulation of abnormal p53 protein with in the cell and also estimates the 
levels of normal p53 protein. 
The potential use of p53 in the future seems to be as a predictive 
factor. Patients with p53 mutations found to reduced response to tamoxifen 
[64],
 whereas taxane based chemotherapy have been associated with greater 
efficacy in people with p53 mutated breast carcinomas. 
[65].
 
  Hence, in future, evaluation of p53 status has one of the powerful 
markers to ameliorate the management of breast carcinoma. 
ANGIOGENESIS: 
The ability of a tumour to induce formation of new microvessels 
called angiogenesis, more than 30 years ago its importance for tumour 
growth was reported 
[69].
.  
Angiogenesis induces the growth of both primary and metastatic 
tumours by different types of mechanisms. 
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• Tumour growth more than 1-2 mm
2
 size
 
is depends on tumour 
angiogenesis 
[64].
.In the absence of tumour microvessels, tumour 
growth is restricted by reduction of nutrients and accumulation of 
waste products.  
• The tumour microvessels permits tumour cells to invade in to blood 
stream
[69, 70],
 paved an initial pathway for distant metastases.  
• Endothelial cells in the tumour microvessels releases growth factors 
which induce further growth of the tumour 
[68].
Tumour 
neovascularisation also involved in the synthesis of various proteolytic 
enzymes 
[74]
 
Tumour angiogenesis is regulated by large number of pro angiogenic 
and antiangiogenic factors, vascular endothelial growth factor(VEGF) is one 
of the most important regulating factor 
75. 
VEGF act as a mutagen for tumour endothelial cells. 
  High levels of vascular endothelial growth factors are associated with 
bad prognosis in breast carcinoma. 
76-81. 
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The factors that regulating the angiogenesis are tabulated as follows: 
TABLE-3 FACTORS REGULATING ANGIOGENISIS :
 
   
  PROANGIOGENIC FACTORS 
 
  
 ANTI ANGIOGENIC FACTORS 
 Vascular endothelial growth factor    angiopoeitin 
 Fibroblast growth factor    angiostatin 
 platelet derived growth factor    endostatin 
 Plasminogen activator inhibitor    thrombospondin 
   Angiogenin     Platelet factor 4 
  Plasminogen activators     Prolactin  
 Transforming growth factor     osteopontin 
  Interestingly, Linderholm and co-workers, revealed that p53 mutation 
associated with high levels of vascular endothelial growth factors. so, the 
p53 gene exerts a inhibitory effect on tumour angiogenesis, wild type p53 
protein found to be inhibit the formation of VEGF( vascular endothelial 
growth factor)
. [82,83].
 
It has been showed that wild-type p53 protein upregulates the  
thrombospondin1, a strong antiangiogenic factor of angiogenesis 
[83]
. 
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So, when mutant p53 protein is present, causes inhibitory effects on 
thrombospondin 1 and subsequently increased tumour angiogenesis 
[83, 84]
. 
Evaluation of tumour angiogenesis by a histological grading system 
and microvessel density grade has been correlates with certain clinico 
pathological entities like tumour size, tumour grade was described 30 years 
ago 
[85]
. 
Weidner and co-workers were the first proposed the method for 
estimation of tumour angiogenesis 
[17].
. They revealed that tumour 
microvessels can be highlighted with help of immunohistochemistry, by 
staining the tumour sections with an antibody against antigen expressed by 
tumour endothelial cells. The microvessel density is then evaluated by 
counting these identified microvessels within the region with the most 
intense new blood vessels, also called hotspots. 
Most of the studies proved that microvessels density can predict bad 
prognosis in breast carcinoma
. [ 86-90]
 including lymph-node negative patients 
[90-96]
.Whereas, some researchers could not find any prognostic significance 
of tumour microvessels density 
[97-101].
 The reason for this results variation 
may be due to diferrent methods were used to estimate microvessels density. 
Indeed, some studies reported contradictory results in the association 
between microvessels density and prognosis. However, most of the studies 
showed that there is a strong association between high microvessels density 
and metastases. 
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Although some studies reported poor correlation between microvessel 
density and lymph node metastases 
[102-103],,
 this relationship is of interest as 
the factors that associated with lymph-node metastases could be used for 
prediction of lymph-node metastases.  
Thus a predictive factor is useful in identifying woman with low risk 
of metastases to avoid unnecessary axillary surgery and also defining the 
woman with high risk of lymph node metastases. 
Moreover, the interest in the therapeutical aspect of angiogenesis has 
been focused on the development of specific anti-angiogenic drugs
 [104, 
105]
although there have been some reports on the predictive value of 
angiogenesis 
[106-110] 
but in search for a new class of antiangiogenic drugs is 
still to be awaited. 
TYPES OF ANGIOGENESIS: 
There are 2 types of angiogenesis, they are 
1. Intussusceptive angiogenesis 
2. Sprouting angiogenesis 
INTUSSUSCEPTIVE ANGIOGENESIS: 
Intussusceptive angiogenesis is otherwise known as splitting type of 
angiogenesis because it splits the vessels in two by direct extension of the 
vessel wall in to the lumen of the already preexisting vessels. 
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 It is very fast and efficient compared with sprouting angiogenesis 
because it requires only rearragement of already pre existing endothelial 
cells and does not depends on endothelial cell migration and proliferation.  
Intussusceptive angiogenesis plays an essential role in formation of 
new vessels in embryos where resources are limited and growth is fast 
[111-
112].
Its occurrence is based upon the formation of tissue pillars. 
  Scanning electron microscopes and three-dimensional reconstruction 
of serial microscopes are useful in identification of transcapillary tissue 
pillars. 
  This type of angiogenesis was discovered in postnatal lungs of rats 
and humans 
[113,114),
 but it also occurs in other tissues and organs like choroid 
of the eye, intestinal mucosa, kidney, ovary, and uterus 
[115,116].
 It also occurs 
in skeletal muscle, heart, and brain. 
  It plays an important role in the formation of vein and artery 
bifurcations and also pruning of larger microvessels. Intussusceptive 
angiogenesis can be identified by determining the frequency of tissue pillars 
from scanning electron micrographs of vascular casts
[116].
. 
SPROUTING ANGIOGENESIS: 
The first discovery of sprouting angiogenesis in growth of the tumour 
was reported by Ausprunk and Folkman, 1977, which consists of following 
steps: 
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i. The basement membrane is locally degraded on the side of the 
peritumoral postcapillary venule situated nearer to the angiogenic 
stimuli; 
ii. Cell to cell contacts between endothelial cells are loosened and 
endothelial cells transmigrate into the surrounding extracellular 
connective tissue matrix; 
iii. Endothelial cells in the extracellular connective tissue matrix form 
solid cord;  
iv. Finally, The formation of lumen takes place infront of the migrating 
portion, newly tubular spuds contact each other and joins to form 
functional capillaries, along basement membrane synthesis and 
rimming of pericytes around basement membrane. 
  Ausprunk and Folkman were first to proposed that tumour vessel 
spuding can advanced without cell division in the early stage of angiogeneis, 
while further outgrowth and prolonged sprouting requires proliferation of 
endothelial cells. 
A large number of in vivo and in vitro models of angiogenesis have 
been introduced with the advancement in this field. In in vitro assays, the 
most common methods in use are,  
i. rabbit cornea by Muthukkaruppan and Auerbach, 1979
117
, 
ii. developing mouse retina by Fruttiger, 2007
118
, and 
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iii. intersegmental vessel growth in zebrafish by Lawson and Weinstein, 
2002
119,120
. 
  Cimpean et al in 2010
121
 has studied selected aspects of the 
angiogenesis with an isolated cell lines which includes endothelial cell 
migration,endothelial cell proliferation, degradation of the connective tissue 
matrix and formation of capillaries. 
Grant et al
122
, first demonstrated the 3 dimensional structure of 
capillary networks and highlighted the membranes of endothelial cells with 
help of light and electron microscopes. 
  In1991, Paku and Paweletz 
123
,
 
they proposed steps in sprouting 
angiogenesis by integrated with the studies of Ausprunk and Folkman, as 
follows:  
1. A structural change in the basement membrane takes place, there is a 
loss of polarity along the whole surface of the dilated blood vessel, 
followed by a loss of the basement membrane at site where endothelial 
cell processes are protruding into the extracellular connective tissue; 
2. Endothelial cells are lined up in parallel manner, forming a small 
lumen and maintaining their basal-luminal polarity by intact 
endothelial junctions; 
3. The polarized endothelial cells are continuously synthesis basement 
membrane all over the sprouting blood vessels, except at the tip of 
developing capillary bud, 
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4. Thereafter, pericytes are recruited over the basement membrane of the 
developing capillaries, 
5. Finally, the growing capillary bud transforms in to a new vessel. 
Accordingly to this model, 2 types of cells are involved in sprouting 
angiogenesis,  
1. “tip cell”  
2. “stalk cell”.  
Tip cells are polarized and migratory in nature. Stalk cell undergoes 
proliferation during capillary sprouting and forms the new lumen of the 
blood vessels.  
The phenotypic differentiation between tip cells and stalk cells is not 
permanent and reversible, it depends on the balance between pro-angiogenic 
factors like vascular endothelial growth factor and Jagged-1, and anti 
angiogenic factors like delta-like ligand 4-Notch activity,as proposed by 
Eilken and Adams in 2010, Geudens and Gerhardt in 2011, Wacker and 
Gerhardt et al 2011 
124,125,126,127
.  
Tip cells usually express high levels of delta-like ligand 4, platelet 
derived growth factor-b (PDGF-b), unc-5 homolog b (UNC5b), VEGF 
receptor-2 (VEGFR-2), and VEGFR-3/Flt-4, and have low levels of Notch 
signaling activity according to Gerhardt et al., 2003
128
.  
The tip cell extend enormous filopodia, these structures guide the 
newly formed blood vessel in a particular pathway toward an stimulus, 
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further it divides and multiplies and while moving it adopts a complex 
branched structure. 
Stalk cells have lesser filopodia than tip cells. They are highly 
proliferative than tip cells, divides in to vascular lumen and branches. They 
also form junctions with adjacent endothelial cells and produce substances of 
basement membrane materials. (Phng and Gerhardt, 2009)
128
. 
During the transformation from active to inactive endothelial cells tip 
cell transformed in to a “phalanx” phenotype, which resembles like a 
phalanx formation of Greek soldiers, that is static cells, which stabilizes the 
blood vessels through tight cell to cell attachment and promotes the integrity 
of blood vessels and also resists the action of VEGF( vascular endothelial 
growth factor). Bautch, 2009 and Mazzone et al., 2009
129
. 
 
   
 
 
 
 
 
 
Fig 13 :  Molecular Mechanism Of Sprouting Angiogenesis 
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TUMOUR ANGIOGENESIS: 
Angiogenesis is a process involving interaction between endothelial 
cells, angiogenic factors, and extracellular matrix. 
For the formation of new capillaries, endothelial cells of existing 
blood vessels should degrade the basement membrane and enter into the 
stroma of the surrounding tissue. These processes of invasion of endothelial 
cells and migration needed a integrative activity between proangiogenic 
system and the matrix metallo protease system.  
1. The first group of proangiogenic factors are vascular endothelial 
growth factor family and the angiopoietins, which directly act on 
endothelial cells. 
2. The second group of factors consists of directly acting substances, 
which includes many chemokines, cytokines, and angiogenic enzymes 
that activate a large number of target cells.  
3. The third class of angiogenic factors are indirectly acting molecules, 
their effects are results from the release of directly acting substances 
from endothelial cells, macrophages, and tumor cells. 
Thus, Tumor angiogenesis is a network of proliferation of blood 
vessels that invades into tumour, providing nutrients and oxygen and 
draining waste substances, has been recognised as one of the hallmark of 
carcinoma -Hanahan and Weinberg, 2011
(105)
.  
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Tumor growth and metastasis depend on angiogenesis and 
lymphangiogenesis stimulated by chemical signals from tumor cells in the 
rapid growth phase Folkman 1971et al
(130)
. 
  In a study, muthukaruppan and colleagues
(117)
 were analysed the 
behavior of tumour cells injected into different foci of the same organ. The 
tumour cells devoid of blood circulation grew only up to a diameter of 1–2 
mm
3
 and but when placed in an area where angiogenesis taken place, it grew 
more than 2 mm
3 
of diameter. 
Holmgren et al 1995
131
 and Parangi et al 1996
(132)
 showed that in 
absence of angiogenesis, tumors may become necrotic. Therefore, 
angiogenesis is an important factor in the tumour growth. 
There are four steps in development of tumour angiogenesis, they are 
as follows,  
1. The basement membrane of endothelial cells is locally injured.  
2.  Endothelial cells activated by pro angiogenic factors and migrate in to 
the area of neovascularisation. 
3.  Endothelial cells proliferate and stabilize.  
4.  Proangiogenic and anti angiogenic factors continue to regulate the 
whole angiogenic process.  
According to denekemp et al, endothelial cells in the mature blood 
vessels proliferates at a rate of every 1000 days on average
(133)
. 
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Thus, the angiogenesis is stimulated when tumor tissues require 
nutrients and oxygen. Angiogenesis is controlled by both activator and 
inhibitor molecules.  
IMMUNOHISTO CHEMISTRY IN DETECTION OF 
NEOVASCULARISATION:        
 IMMUNOHISTOCHEMISTRY : 
The principle of IHC has been known since the 1930s, but it was only 
in 1942 that the first Immunohistochemistry study was reported. Coons et al 
in 1942, first used FITC-labeled antibodies to detect Pneumococcal antigens 
in infected tissue. 
IHC is used for diagnosis of disease, development of drugs and 
biological research. Using specific tumor markers, clinicians use 
Immunohistochemistry to diagnose a cancer as benign or malignant, 
determine the stage and grade of a tumor, and identify the cell type and 
origin of a metastasis to find the site of the primary tumor. 
Immunohistochemistry (IHC) or immunocytochemistry is the 
application of immunologic principles and techniques to demonstrate 
specific antigens in cells and tissue based on the antigen antibody interaction 
and it exploit the specificity at light microscopic level
1
. 
Immunohistochemistry play an important tool in identification of new 
vessels.  
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Major components in a immunohistochemistry : 
1. Primary antibody binds to specific antigen 
2. The antibody-antigen complex is formed by incubation with a 
secondary, enzyme-conjugated, antibody 
3. With presence of substrate and chromogen, the enzyme catalyzes to 
generate colored deposits at the sites of antibody-antigen binding. 
Various stages of development of Immunohistochemistry include 
peroxidase – antiperoxidase method (1970), alkaline phosphatase labeling 
method(1971), avidin biotin method (1977) and two layer dextrin polymer 
technique(1993). 
Steps of immunohistochemistry: 
Antigen retrieval : 
Antigen retrieval is done to unmask the antigen determinants of fixed 
tissue sections.This can be done by 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
3. Microwave and trypsin antigen retrieval 
4. Pressure cooker antigen retrieval 
Proteolytic enzyme digestion: 
Enzymes like trypsin and proteinases are used to breakdown the 
formalin cross linkages and unmask the antigen determinants.But there is a 
disadvantage of antigen destruction and inadequate digestion. 
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Microwave antigen retrieval: 
In this formalin fixed paraffin sections are boiled in various buffers for 
rapid and uniform heating. Currently this is the most common method used. 
Pressure cooker antigen retrieval: 
In this method also the tissue sections are boiled in buffers to unmask 
the antigens. This method is used to retrieve large number of slides. 
Detection systems: 
After adding specific antibodies to the antigens, the antigen antibody 
complex should be detected.This is done by direct and indirect methods. 
Direct method: 
The primary antibody is directly conjugated with 
flurochrome.Commonly used flurochromes are horse radish peroxidase and 
alkaline phosphatase.  
Indirect method : 
It is a two-step method. 
  First the labeled secondary antibody reacts with primary antibody 
which is bound to specific antigen. The use of peroxidase enzyme complex 
or avidin biotin complex further increases the sensitivity of 
immunohistochemical stains. 
There are certain drawbacks are associated in evaluation of 
microvessel density in breast cancer, 
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According to Astekar et al., (2012), 
[134]
 differences between various 
studies could be due to different antibodies used like CD 31, CD 34 and 
factor VIII by authors to define endothelium and different methodologies 
used in assessment of various parameters.  
Tae et al., in 2000, 
[135]
 stated lack of a standardized direct method to 
measure angiogenesis as a factor. Also none of the existing methods can 
differentiate between resting and active angiogenic vessels. 
Astekar et al., 
[136]
 also stated that differences between 
immunohistochemical protocols, like selection of the paraffin block, level of 
section within the tissue block, that is, superficial or deep and variability in 
the selection of hot spot identification may contribute to the variation of the 
results. 
 Therefore, we needed new endothelial cell markers that would detect 
only active neoangiogenic vessels. 
ROLE OF CD 34 IN DETECTION OF MICROVESSELS 
DENSITY: 
CD34 molecule is a cluster of differentiation molecule present on 
certain cells within the human body. 
Cd 34 also known as haematopoietic progenitor cell antigen 34. It is a 
glycosylated type I protein comprosed of 385 aminoacids and having a 
molecular weight of 41 kDa encoded on the gene 1q32. 
There are two forms as result of alternative splicing. 
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Cd34 is expressed on haematopoietic stem cells of all lineages, as well 
as most primitive stem cells. 
Cd 34 antigen also found in dermal dentrocytes, interstitial cells, 
endometrial stroma, endothelial cells of blood vessels, hepatic sinusoids, 
fibroblasts. It also expressed in hemangiomas, epitheloid 
hemangioendothelioma, Kaposi sarcoma, angiosarcomas. 
Commercially available preparations are My 10,qb end/10, bi -3c5, 
4H11,43A1 and TUK3 and few rabbit monoclonal antibodies EC373Y. 
da Silva BB et al stated that the mean microvessel densities with anti-
Factor VIII, anti-CD31 and anti-CD34 were 4.16, 4.09 and 6.59 respectively. 
The density and intensity of staining of anti-CD34 is also greater compared 
to anti-CD31 and anti-factor VIII-related antigen.
(137) 
DEVELOPMENT OF QUANTITATIVE ASSAYS FOR 
ANGIOGENESIS: 
 In the year 1980 Folkman and his colleagues successfully established 
the appropriate conditions to grow endothelial cells in culture medium, and 
used them to determine the functional steps in angiogenesis 
(138).
 Thereafter a 
number of quantitative and semi quantitative assays have developed that 
involve sprouting angiogenesis in non tumourous cells 
(139),
 like  
• corneal micropocket assay  
• the subcutaneous `Matrigel plug' assay 
(139)
  
65 
 
• assays involving growth of cut sections of blood vessels in three 
dimensional gels of an extracellular matrix.
(140).
  
The introduction of these systems has led to the discovery of new 
proangiogenic and anti angiogenic factors 
CLINICAL APPLICATION: 
Though, microvessels density is used as prognostic factor in breast 
carcinoma, microvessel count has not been proved to be a acceptable 
parameter to estimate antiangiogenic treatment.  
The assumptions that the degree of tumour angiogenic activity is 
proportional to the degree of microvessel count and that the quantification of 
microvessel density will gives the much needed information for 
antiangiogenic therapy, have led to two misconceptions : 
1. The level of microvessels density in untreated tumour can asses the 
response to antiangiogenic treatment, 
2. Microvessels density could evaluate the efficacy of the antiangiogenic 
drugs. 
Microvessel density varies widely with tumor type. The growth of all 
tumor types depend on a therapeutically targetable angiogenic process. 
  According to Rajkumar SVet al, Munshi NC
141
 et al,the growth of the 
tumour depends on the levels of oxygen exchange and nutrient supply,which 
indirectly reflects the intensity of tumour angiogenesis.  
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The metabolic demands of tumour cells vary with the tissue of origin 
and change with tumor progression. Thus, the number of tumor cells that can 
be supported by a vessel varies, influencing, in turn, the vascular density of 
the tumour.  
Beecken WD, Fernandez A et al.
142
 showed that tumour with both 
high and low level of microvessel density can respond to antiangiogenic 
treatment. 
According to studies conducted by Folkman J, Hahnfeldt Pet al B
143
, 
growth of all tumors depend on angiogenesis, hence tumour with low 
microvessel counts are not an appropriate criteria to omit patients from 
treatment with antiangiogenic agents.  
A common misconception is that measurement of microvessel density 
made during antiangiogenic therapy may be used to evaluate the therapeutic 
response to antiangiogenic agents. 
However, the efficiency of an antiangiogenic drug cannot be estimated 
by simply measuring the changes in microvessels count alone. This is 
because changes in microvessels density reflect the change in the ratio of the 
tumour vascularisation to its tumor-cell component. 
Under antiangiogenic therapy, elimination of capillary occurs first, 
followed by elimination of tumour cells, and both make an impact on the 
measurement of microvessel density.  
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Thus, decrease in microvessel density while on treatment with an 
antiangiogenic drug implies that the drug is active, though microvessel 
density would not predict the tumor response to antiangiogenic therapy. 
Currently, there is a wide range of investigations being carried out to 
find the basic biology of angiogenesis
 (144-147)
, to provide further insights into 
the effective use of antiangiogenic drugs 
(148) 
.Thus,antiangiogenic agents are 
classified in to different types based on the target 
(149)
, mode of action, or 
stage of cancer most appropriate to antiangiogenic agents in order to provide 
a standard guidelines for using combination therapy. 
(150-152)
, hence in order 
to resolve, supplementary assays may be needed other than microvessels 
density for evaluating the efficiency of antiangiogenic drugs. 
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Methodology 
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MATERIALS AND METHODS 
This is a both retrospective and prospective study was conducted in 
the Department of Pathology, Tirunelveli Medical College for a period of 
about 24 months from june 2012 to june 2014. From 225cases of breast 
specimens 50 cases of breast specimens with known malignancy were 
randomly selected and examined, which included 30 cases of lymph node 
positive breast carcinoma specimens and 20 cases of lymphnode negative 
breast carcinoma specimens. This study was conducted after obtaining 
clearance from the Institutional Ethical Committee. 
Immunohistochemistry was done on all the 50 cases inorder to findout 
microvessels in intratumoural and peritumoural area with cd 34 marker. 
INCLUSION CRITERIA: 
Cases of breast carcinoma were included.  
IMMUNOHISTOCHEMICAL TECHNIQUE : 
  Immunostaining with the endothelial cell marker CD34 was 
performed following an avidin-biotin immunoperoxidase procedure. 
Primary Antibody Kit:  
Specificity : Human endothelial cells-CD34 antigen 
Clone : QBEnd/10  
Ig Class : Ig G1  
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Antigen used for immunization  : Detergent solubilized vesicular suspension  
   prepared from a perfusate of human   term     
   placenta.  
Hybridoma Partner  : Mouse Myeloma. 
Preparation : Lyophilised tissue culture supernatant  
   containing 15 mmol sodium azide.  
Effective on paraffin wax embedded tissue. 
Secondary Antibody Kit :  
Contains 
1. 3% Hydrogen Peroxide, 
2.  Phosphate-buffered saline with stabilizers,  
3. Polymer penetration enhancer -10% (v/v) animal serum in tris 
buffered saline (0.09%), 
4.  Anti-mouse/rabbit IgG-Poly-HRP, 
5.  DAB Chromogen 1.74% w/v 3,3’-diaminobenzidine, 0.02% 
Hematoxylin.  
Reagents required but not supplied in secondary antibody Kit 
include Standard solvents used in immunohistochemistry, 50 mM tris 
buffered saline (TBS), Antigen retrieval solution, Enzyme retrieval 
solution, Antibody diluents, Primary Antibody, Mounting medium. 
The primary monoclonal antibody was used at a dilution of 1:500       
(DAKO Envision, Santa Cruz Biotechnology), previously slides were treated 
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by incubation in pressure cooker for 20 minutes at 1.5 atmospheres with 
citrate buffer pH 6.1. After washing the samples three times with Tris 
Buffered Saline (TBS), release reaction was made by adding DAB 
chromogen (3,3'diaminobenzidine) as a chromogen staining substrate for 5-
10 minutes. Tissue sections were counterstained with hematoxylin. 
Day 1 Procedure:  
Sections are cut from paraffin embedded tissue blocks. Blocks are 
fixed in egg albumin coated slides.Slides are kept in hot air oven overnight at 
60°C.  
Day 2 Procedure:  
• Make up citrate buffer by adding anhydrous citric acid 1.92 grams in 
1000 ml of distilled water. adjust the ph to 6.2 with 1 N of sodium 
hydroxide. 
• Then, make up TRIS saline buffer by TRIS 0.605 grams and 8 grams 
of NaCl in 1000ml of water, add 4 ml of 1 N Hcl.maintain the Ph for 
7.6. 
• Slides were deparaffinized with four washes of xylene. Slides are 
rehydrated by propanol.  
• Slides rinsed in running tap water. 
• Slides were kept in citrate buffer, in the pressure cooker for antigen 
retrieval for 20-25 minutes and then cooled for 15 minutes.  
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• Slides were treated with Hydrogen Peroxide for 5-10 minutes for 
elimination of endogenous peroxidase activity.  
• Slides were rinsed in running tap water for 5-10 minutes.  
• Slides were incubated with TRIS buffer saline for 5 minutes.  
• 50 µl of NRS (1:10) was added to block non-specific binding sites and 
kept for 20 minutes.  
• Primary antibody added with dilution and kept for 1 hour.  
• Sections are soaked in Tris buffer for 10 minutes  
• Suitable Polymer penetration enhancer was added and kept for 15 
minutes, again wash with tbs for 3 min.  
• Incubate with secondary antibody (igG-poly-HRP), 20 min. at room 
temperature.  
• Three changes of tris buffer for five minutes.  
• Stain with diaminobenzidin (DAB) solution, 5-10 min. at room 
temperature.  
• Wash the slides with running tap water for 2-3 min.  
• Counterstain with Mayer's hematoxylin, 3 dips. 
• Again wash the slides with running tap water.  
• Dehydrate with upgrading concentration of ethanol: 50%, 70%, 96%, 
absolute, 3 min. each.  
• Clear with xylene.  
• Mount with DPX and view. 
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MORPHOMETRIC ANALYSIS: 
To quantify vessel neoformation we used hot spot method according 
to Weidner method. 
After CD34 staining, each case was evaluated in order to select the 
area with the highest vascularization. For this purpose a scope image 9.0exe 
microimaging device was used. 
Brown-stained cell groups clearly distinguishable from the 
background were counted as one vessel. All groups of cells positive for 
CD34 endothelial cell marker but without an evident lumen, were considered 
as undifferentiated vessels. Vascular hot spots were identified at a low 
optical power using a 4x and10x objective. Four equal areas of high 
vascularization were photographed with a 10x objective. 
Measurements were performed using the Scope image 9.0 exe Image 
Analysis System. 
Any artifacts occurring in the samples were removed manually. 
Vessels were identified according to caliber into the following 
categories: 
• Capillaries: Max.diameter- 8-15 µm 
• Arterioles: Max.diameter- 15-50 µm 
• Small Arteries: Max.diameter - 50-200 µm  
was considered for area. 
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DIGITAL EVALUATION OF MVD : 
The recorded slide images of each case were manually assessed using 
scope image 9.0 exe software and measurement scales were calibrated for 
4x, 10x and 40x power. The average MVD, average lumen area (µm2), 
average vascular area (µm2), and median vessel wall thickness (µm) were 
measured. MVD was defined as number of vessels per square-millimeter. 
Vascular area was defined as the sum of the areas of all the endothelial cells 
of a vessel. Adjusted MVD as defined by Tanigawa was obtained using 
microvessel density × mean vessel perimeter (µm) / 40 (µm). 
 
STASTICAL ANALYSIS: 
                            The data were statiscally analysed using spss statistical 
software. Two talied student t test and one way ANNOVA test were used to 
asses the association between two quantitative variable. Kendall tau rank 
correlation coefficient test was used to measure association between two 
measured quantities. The p-value less than 0.05 were considered significant. 
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OBSERVATION AND RESULTS 
This is a both retrospective and prospective study was conducted in 
the histopathology Laboratory of the Department of Pathology, Tirunelveli 
Medical College for a period of 24 months and the following observations 
were made. 
TABLE 3- BREAST SPECIMENS VS OTHER SPECIMENS 
Duration 
Total Number 
Of Specimens 
Number Of 
Breast 
Specimens 
Percentage 
June2012-
December 2012 
   
  1870 
   
  48 
  
 2.566 
January2013- 
December 2013 
   
  3518 
   
  122 
  
 3.467  
January 2014-  
june 2014 
   
  1960 
   
  55 
  
 2.806  
   
 Total  
   
   7348 
   
  225 
  
 3.062  
 
 In the study period of 24 months duration from June 2012 to june 
2014, total number of specimens we received are 7438. Out of these 
specimens, the 225 specim
 48 cases of breast s
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TABLE 4- AGE DISTRIBUTION OF BREAST CARCINOMAS 
Age Groups Number Of Breast Carcinomas Percentage (%) 
30-39 yrs       2 4% 
40-49 yrs      17 34% 
50-59 yrs      19 38% 
60-69 yrs      9 18% 
70-79 yrs      3 6% 
 Mean age = 52.58  
 
By dividing the age group of patients into five categories, we observed 
that breast carcinomas were more common in the age group of 50 – 59 years 
with 19 cases constituting 38%, followed by the age group of 40 – 49 years 
with cases comprising 34 % and next to follow is the age group of 60 – 69 
years with 9 cases constituting 18%. The youngest patient in our study is 35 
years old and the oldest patient in our study is 75 years of age. We arrived at 
a mean age of 52.58 years for occurrence of breast carcinoma in our study. 
These findings are tabulated in Table 4 and Chart 2. 
  
CHART 2- AGE DIS
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TABLE 6- HISTOLOGY GRADE vs TUMOUR SIZE 
Size of 
tumour (cm) 
Grade I (%) 
Grade II 
(%) 
Grade III 
(%) 
Total Percentage 
<2 (T1) 1(50%) 1(2.5%) 0 2 4% 
2– 5 (T2) 1 (50%) 26 (65%) 1(12.5%) 28 56% 
>5 (T3) 0 13 (32.5%) 7 (87.5%) 20 40% 
Total 2 40 8 50 100% 
 
 The association between histological grade and tumour size was made 
in the Table 6and Chart 5, which revealed most of the tumours (56%) to be 
in T2 (2 – 5cms) size. Among the Grade I tumours 50% (1 cases) were in T2 
and 50% (1cases) were in T1. Among the Grade II tumours 65% (26 cases) 
were in T2 and 32.5% (13 cases) were in T3. Among the Grade III tumours 
12.5% (1 cases) were in T2 and 87.5% (7case) was in T3 size. On applying 
the chi square test for statistical significance the P-value was 0.001 – sig. 
Hence the correlation between histological grade and tumour size was 
significant.  
 
 CHART 4- HIST
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 The Table 7 and Chart 5 depicts that grade III tumours were more 
common in the age group of 50 to 59 years followed by the age group of 40 
to 49 years constituting 16.7%. The age group of 40 to 49 years is the most 
common age group affected in both grade I (100%) and grade II (46.2%) 
tumours. Statistical calculation were analysed by chi-square method, there 
was no statistical correlation between patient age and tumour grade (P-value 
– 0.088411> 0.05 – Not sig). 
TABLE8- HISTOLOGY GRADE vs LYMPH NODE STATUS 
 
Lymph node 
status 
 
Grade I (%) 
 
Grade II (%) 
 
Grade III (%) 
 
Total 
 
Percentage 
Positive   1(50%)  21(42.3%)  8(100%) 30 42.5% 
Negative  1 (50%)  19 (57.7%)  0 20 57.5% 
Total 2 40  8 50 100% 
  
Among the grade I tumours 50% showed negative lymph node status 
and 50% showed positive lymph nodes. On the other hand grade III tumours 
showed 100% positive and 0% negative lymph node status. Grade II tumours 
showed equivocal findings with 42.3% showing lymph node positivity and 
57.7% showing lymph nod
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TABLE- 10- MICROVESSEL COUNT –INTRATUMORAL VS 
PERITUMOURAL. 
      MICROVESSELS COUNT   
   
  Mean 
Standard             
Deviation 
 
 Range 
 
 P-Value 
 
INTRATUMOURAL  
MICROVESSELS. 
   
  70.2  
 
 28.17 
    
  22-134 
 
 
p-0.001 
 
PERITUMOURAL   
MICROVESSELS. 
   
  91.58 
 
 28.09 
 
  45-174 
The mean microvessels density within the tumour has lesser number 
of microvessels as compared to Peritumoural area. The mean microvessels 
density in intratumoral area is 70.2 with standard deviation of 28.17 where as 
the mean microvessels density in peritumoural area is 91.58 with standard 
deviation of 28.09. p – value for both these group were analysed by paired 
student t- test, it was found to be <0.001 (statistically significant). 
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TABLE-11 : PERITUMOURAL MICROVESSEL COUNT VS 
TUMOUR SIZE 
   PERITUMOURAL MICROVESSELS COUNT 
 
Tumour Size 
 
No. Of Breast 
Carcinomas 
 
Mean Value 
 
Standard 
Deviation 
 
P- Value 
  
 <2 cm 
  
  2 
  
 61.5 
 
7.778 
  
 
 p-0.240 
 
 
 2-5 cm 
  
  28 
 
87.607 
 
24.914 
 
 >5 cm 
   
  20 
 
93.6 
 
28.059 
There was a poor correlation between the MVD values and the tumour 
size. The mean values of peritumoural microvessels counts increased 
gradually as the size of the malignant neoplasm increased, with T1 lesions 
showing a microvessels count of 61.5, T2 lesions showing a microvessels 
count of 87.607 and T3 lesions showing the highest mean peritumoural 
microvessels count of 93.6. But, the correlation between peritumoural 
microvessels count and the size of the breast neoplasm was not stastically 
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significant with (P-value – 0.240 >0.05 ). These observations were analysed 
by one way- ANNOVA test and it is depicted in table-11. 
TABLE -12:PERITUMOURAL MICROVESSELS COUNT VS 
TUMOUR GRADE 
 
  
  Tumour  
  Grade 
  PERITUMOURAL MICROVESSELS COUNT 
 
No. Of Breast 
Carcinomas 
   
  Mean 
 
Standard 
Deviation 
 
P- Value 
 Grade-1     2  61.5  7.7  
 
p-0.126 
 Grade-2    40  87.8  27.36 
  Grade-3    8  101.625  15.436 
 
The microvessels counting was done on 50 cases which revealed mean 
peritumoural mirovessels count of 61.5 in grade 1 tumours, while mean 
peritumoural microvessels count was higher in grade 3 with a score of 
101.625+/-15.436. The mean peritumoural microvessels count showed 
higher values in grade 3 tumours compared to grade1 breast carcinomas. 
Peritumoral microvessels count and grading of tumours were analysed by 
one way-ANOVA test,it was not statistically significant(P value – 0.126 ), 
90 
 
however it has shown a positive correlation between tumour grade and 
microvessels density, analysed by kendals rank correlation coefficient 
method. These findings are tabulated in Table 12. 
TABLE-13:PERITUMOURAL MICROVESSELS COUNT VS LYMPH 
NODE STATUS 
  PERITUMOURAL MICROVESSELS COUNT 
 
Lymph Node 
Status 
 
No. Of Breast 
Carcinomas 
  
Mean Value 
 
Standard 
Deviation 
  
 
P- Value 
  
Positive 
   
  30 
 
 103.2 
 
 
 21.063 
 
  
 
p-0.001 
  
Negative 
   
  20 
 
  69.15 
 
 17.31 
 
 
The patients with positive lymph node status shows higher 
Peritumoural Microvesssels count compared to patients with negative 
lymphnode, the mean Peritumoural microvessels count for node positive 
status is 103.2 where as 69.15 in node negative status,two groups were 
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compared by paired student-t test, the results were found to be stastically 
significant with p- value -0.00001(significant).Peritumoral microvessel 
density values with regard to lymph node status are shown in Table 13 
TABLE 14: PERITUMOURAL MICROVESSELS COUNT VS AGE 
  PERITUMOURAL MICROVESSELS COUNT 
   
  Age 
 
No. Of breast 
carcinomas 
 
Mean value 
 
Standard 
deviation 
 
P- Value 
 30-39    2 72.5  7.77   
 
p-0.884 
 40-49   17 92.118  31.07  
 50-59   19 86.7  23.036  
 60-69    9 91.8  27.2 
 70-79    3 90.3  26.57  
 
The Table 14 depicts that mean value of peritumoural microvessels count 
were92.118 in the age group of 40 to 49 years followed by the age group of 
60 to 69 years constituting 91.8. The age group 30 to 39 which have the least 
mean peritumoural microvessels count of 72.5. There was no statistical 
significance between patient age and peritumoural microvessels count  
p-0.884. 
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TABLE-15 :INTRATUMOURAL MICROVESSEL COUNT VS 
TUMOUR SIZE 
   INTRATUMOURAL MICROVESSELS COUNT 
 
Tumour Size 
 
No. Of Breast 
Carcinomas 
 
Mean Value 
 
Standard 
Deviation 
 
P- Value 
  
 <2 cm 
  
  2 
  
 33 
 
15.556 
  
 
  
p-0.156 
 
 2-5 cm 
  
  28 
 
69.214(25-
12O) 
 
27.03 
 
 >5 cm 
   
  20 
 
76.500(27- 
134) 
 
29.752 
There was a poor correlation between the MVD values and the tumour 
size. The mean values of intratumoural microvessels counts increased 
gradually as the size of the malignant neoplasm increased, with T1 lesions 
showing a microvessels count of 33, T2 lesions showing a microvessels 
count of 69.214 and T3 lesions showing the highest mean microvessels count 
of 76.500. But, the correlation between microvessels count and the size of 
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the breast neoplasm was not stastically significant with (P-value – 0. 156 
>0.05 ). These observations were depicted in table 15 
TABLE -16: INTRATUMOURAL MICROVESSELS COUNT VS 
TUMOUR GRADE 
 
   
  Tumour  
  Grade 
  INTRATUMOURAL MICROVESSEL COUNT 
 
No. Of Breast 
Carcinomas 
   
  Mean 
 
Standard 
Deviation 
 
P- Value 
 Grade-1     2  38(35-45)  7.07  
 
p- 0.005  Grade-2    40  60.75(22-108)  17.02 
  Grade-3    8  93.37(56-134)  25.41 
 
The intratumoural microvessels counting was done on 50 cases which 
revealed mean mirovessels count of 38+/-7.07 in grade 1 tumours, while 
mean microvessels count was higher in grade 3 with a score of 93.37+/-
25.41. The mean microvessels count showed higher values in grade 3 
tumours compared to grade1breast carcinomas. Microvessels count and 
grading of tumours were analysed by one way-ANOVA test,it has shown a 
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stastically significant values, higher values in grade 3 tumours compared to 
the grade -1 tumours (P value – 0.005 ) and the values of intratumoural 
microvessels density correlated well with tumour grade (kendals rank 
correlation co-efficient). These findings are tabulated in Table 16  
 
TABLE 17: INTRATUMOURAL MICROVESSELS COUNT VS 
LYMPH NODE STATUS 
  INTRATUMOURAL MICROVESSELS COUNT 
 
Lymph Node 
Status 
 
No. Of Breast 
Carcinomas 
  
Mean Value 
 
Standard 
Deviation 
  
 
P- Value 
  
Positive 
   
 30 
 
85.63(25-
134) 
 
24.318 
  
 
p-0.00001 
  
Negative 
   
20 
 
47.60(22-79) 
 
15.44 
 
The patients with positive lymph node status shows higher intra 
tumoural microvesssels count compared to patients with negative 
lymphnode, the mean microvessels count for node positive status is 85.63 
where as 47.60 in node negative status,two groups were compared by one 
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way ANNOVA test, the results were found to be stastically significant with 
p- value -0.00001(significant), are shown in Table 13 
 
TABLE-18 - INTRATUMOURAL MICROVESSELS COUNT VS AGE 
   INTRATUMOURAL MICROVESSELS COUNT 
  Age No. Of Breast 
Carcinomas 
Mean Value Standard 
Deviation 
P- Value 
 30-39    2 49.5  6.364  
 
 p-0.825 
 40-49   17 73.25(22-134)  33.007 
 50-59   19 67.947(25-
112) 
 26.328 
 60-69    9 71.556(25-
119) 
 32.639 
 70-79    3 68.33(43-96)  26.577 
 
The Table 18 depicts that mean value of intratumoural microvessels 
count were 73.25 in the age group of 40 to 49 years followed by the age 
group of 60 to 69 years constituting 71.556. The age group 30 to 39 which 
have the least mean microvessels count of 49.5. ONE WAY –ANNOVA 
showed that here was no statistical correlation between patient age and 
microvessels count p value-0.825..            
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DISCUSSION 
Breast cancer is the leading cause of cancer deaths among women. 
Most of the studies suggested that tumor growth and metastasis in breast 
cancer depends on angiogenesis. 
The American College of Pathologists suggested that an improved 
study on quantification of tumor angiogenesis is needed to demonstrate its 
prognostic value in breast carcinoma. 
Angiogenesis is now growing as an important prognostic indicator in 
tumor progression. It has been stated that the number of micro vessels within 
a tumor gives an estimate of the angiogenic potential of tumor cells, which in 
turn yield the probability of tumor growth, invasion, and metastasis. 
It has been confirmed in many solid tumor types such as melanoma, 
prostate, and breast cancer. Tumor angiogenesis is usually quantified by 
counting the number of micro vessels in tumour sections by 
immunohistochemical methods using endothelial cell markers, such as 
Factor VIII, CD31, CD34. 
Takao Kato et al found that in certain Japanese breast cancer patients, 
especially in node-negative patients, there was a significant independent 
prognostic factor associated with their long term survival
153,161
. 
However, results of various studies on the prognostic value of MVD 
have not been similar, possibly because of factors such as methodological 
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variation, a lack of correct patient follow-up data in retrospective studies, 
bias in selecting areas of tumors for study. 
Degree of vascularisation in different cancers and angiogenesis was 
not uniform within the same tumor. So, the areas with highest micrvessels 
density called hotspots were counted. 
In a study done by H P Dhakal et al
162
 and Fox B et al
163
, the Chalkley 
method appears to be the better method in estimating the prognostic impact 
of vascularity in invasive breast carcinomas 
It has been stressed that the prognostic significance of tumor 
microvessels density must be assesed in a prospective way with a 
standardized methodology.  
As proposed by Weidner et al
156
, we counted the microvessels density 
by finding the vascular hotspots at 40x and point count at 100x 
magnification. we had taken one monoclonal antibody to CD34 and counted 
four fields/0.25 mm2 and the sum of all the four areas were calculated, this 
would give exact measurement of microvessels in the hot spot areas, as 
stated by L Martin et al
152a
. Earlier studies only evaluated in 200x per one 
microscopic field area for micro vessel density and this was analysed by 
statistical methods.  
AS L Martin
152a
 et al concluded that the microvessel density measured 
in histological sections were representative of whole tumour vascularity, 
based on this study we had taken the representative sections from the tumor. 
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Microscopic analysis for tumor areas with greater microvessel density 
establish a better correlation between intra tumoral vascularisation and 
tumor's angiogenic potential, hence we also followed this method.  
Following the original study done by Weidner et al. in 1991, other 
researchers have also revealed the importance of angiogenesis in prognosis 
of breast cancer. In our study, we compared tumour angiogenesis measured 
by microvessels count with various other clinico-pathological factors like 
patient age, tumour size, histological grade, lymph node status, prognosis.  
We also try to find any association between micro vascular count and 
other prognostic factors like Tumor size, axillary lymph node status, Tumor 
type, histologic grade, vascular invasion. 
In this study the mean and median of microvessels density was 70.54 
with a standard deviation of 28 (average Range, 25 to 134) for an area of 1 
mm
2
. The mean and median microvessel counts from the Weidner et al study 
was 60 and 56 (range, 8 to 167), respectively, for a counting area 0.74- 
mm
2
.Whereas Van Hoef et al
157
 got higher ranges of 67 and 101 
respectively, for an area of 0.476- mm2.  
Unlike the study by Horak et al
154
, our study could not find any 
significant relationship between micro vascular density and size of the tumor 
with P value of 0.156. However, A borderline significant correlation 
(P=0.005) between Micro vascular density and high-grade tumours was 
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found by this study similar to that found by Weidner et al, horak et al and 
Bosari et al
154,159,160
. 
In our study we found a statistically significant association between 
the microvessels density and the lymph node status, similar to the studies 
done by Horak et al, and Weidner et al and Bosari et al who found a 
significant relationship between Microvessels count and lymph nodes status.  
Goulding et al
153
, could not find any relationship between the two 
parameters. As a prognostic indicator for breast carcinoma, Bosari et al, 
Horak et al and Weidner et al found a significant difference in                       
overall survival rates between cases with low and high microvessel density.  
However, the association between Micro vascular density and 
prognosis was not found by goulding et al, Van Hoef et al, Costello et al. In 
this study we found the microvessel density was increasing with age but this 
was not significant (P value =0.9).Maxine Orre et al
155
 also observed the 
same results.. 
From the above discussion it can be inferred that there are many 
discrepancies between results obtained by different pathology laboratories, 
and a greater number of these can be ascribed to the variations in 
methodology.  
While counting micro vessels, the choice of antibody for 
immunohistochemical staining is important. The selection of antibody to 
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detect endothelial cells is a midway between the sensitivity and specificity of 
the available markers.  
  A number of studies have been carried out on different endothelial 
markers and none of them have arrived to any universal agreement till now. 
This is because of the various factors viz tissue-processing regime, choice of 
fixative, antigen-retrieval system and visualisation method affecting the 
sensitivity and specificity of all endothelial markers used.  
Majority of the retrospective studies on angiogenesis research in 
breast carcinoma showed that angiogenesis was a crucial new prognostic 
factor in early-stage breast cancer. This should be further studied in 
prospective controlled clinical trials to demonstrate if any adjuvant treatment 
can improve the prognosis of those at high risk. 
The vascular endothelial marker CD34 used in our study to calculate 
the microvascular density which stained the micro vessels greater and more 
intensely as shown by L martin et al in 1997
152a
 and Da silva BB et al in 
2009.  
 Instead of CD 34, the Van Hoef group used antiCD-31 to highlight 
the microvessels. Hence, the microvessel densities obtained by them are in a 
greater range than what would be expected.  
 Horak et al also
154
 revealed anti-CD31 to be the most sensitive 
endothelial marker for highlighting intratumor microvessels. These 
discrepancies are due to the methodological problems. 
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  The design and size of the study also affect the results obtained. Most 
studies of tumour microvessels density in breast carcinoma have used less 
than the 50 patients recommended for analysing its usefulness as a 
prognostic and predictive factors. In our study the number of cases taken was 
fifty, hence we met the required sample size. 
  In the present scenario, microvessel density as a prognostic marker for 
breast cancer is not reliable. Intratumoral new vessel growth appears to be a 
necessary event but not the only prognostic factor for tumour metastasis. 
However, Microvessel count serves as a good prognostic marker to identify 
patients at high risk. 
Though many contradictions and inconsistencies have been interpreted 
in the studies carried out, the majority of them showed that high 
microvessels count correlated well with prognosis, lymph node status and 
histological grade. These differences are due to the variations in the 
investigation methods employed, variability in immune staining, the process 
of selection and counting.  
In the future, antibodies specific to proliferating endothelium, with the 
development of automated image analysis, can improve the accuracy and 
value of measuring angiogenesis-induced microvessel density. 
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SUMMARY 
Angiogenesis is now growing as an important prognostic factor in 
tumor progression. It has been stated that the number of micro vessels within 
a tumor gives an estimate of the angiogenic potential of tumor cells, which in 
turn yield the probability of tumor growth, invasion, and metastasis. 
In our study, we observed statistically significant association between 
the microvessels density and the lymph node status. the mean microvessels 
count for node positive status is 85.63 where as 47.60 in node negative 
status. 
Mean microvessels density was found to be more superior in 
peritumoural area as compared to intratumoural area.we also observed 
positive correlation in microvessel density between peritumoral and intra 
tumoural region.  
There was a poor correlation between the MVD values and the tumour 
size. And also there was no statistical correlation between patient age and 
microvessels count p-0.865. Histological Grade of the tumour has shown a 
positive correlation with intratumoural microvessels density, although they 
are not statistically significant between their groups.  
  However, results of various studies on the prognostic value of MVD 
have not been similar, possibly because of factors such as methodological 
variation, a lack of correct patient follow-up data in retrospective studies, 
bias in selecting areas of tumors for study. 
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Most of the studies stated that there is a lack of a standardized direct 
method to measure angiogenesis as a factor. 
The differences between various studies could be due to different 
antibodies used like CD 31, CD 34 and factor VIII by authors to define 
endothelium and different methodologies used in assessment of various 
parameters.  
Thus, the study of microvessels density gives insight to the tumour 
behaviour related to angiogenesis. Hence, new endothelial cell markers that 
would detect only active neoangiogenic vessels and a standardised 
methodology is needed to evaluate the microvessels density in breast 
carcinoma in future.  
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Conclusion 
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CONCLUSION 
Assessment and evaluation of the microvessel density and their 
parameters in the present study on breast specimens has enlightened us to 
draw the following conclusions- 
• All the vascular parameters showed consistently higher values for high 
grade compared to the low grade tumour of the breast. Mean 
microvessels density was found to be more superior in peritumoural 
area as compared to intratumoural area. 
• The patients with positive lymph node status shows higher 
microvesssels count compared to patients with negative lymphnode, 
the mean microvessels count for node positive status is significantly 
higher than compared with node negative patients. 
Thus, the study shows a positive correlation between the tumour 
angiogenesis and metastasis. 
 In the future, Antibodies specific to proliferating endothelium, 
together with the development of automated image analysis, may improve 
the accuracy and value of measuring angiogenesis-induced microvessel 
density.  
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Appendix 
  
APPENDIX  I 
QUANTIOCATION  MICROVESSEL  DENSITY  IN BREAST  
CARCINOMAS BASED  ON IMMUNOHISTOCHEMISTRY. 
PROFORMA 
PATH NO:________________.  IP/OP NO:___________ 
PATIENT NAME: _____________________________________________                          
AGE : _______ SEX :M/F____ UNIT /WARD:_________ 
ADDRESS:____________________________________________________
_____________________________________________________________
_____________________________________________________________ 
CLINICAL 
DIAGNOSIS:___________________________________________ 
1. PRESENTING COMPLAINTS:______________________________ 
2. PERSONAL HISTORY : ___________________________________ 
3. FAMILY  HISTORY  :__________________________________ 
4. GENERAL EXAMINATION:____________ _________________ 
5. LOCAL  EXAMINATION :_________________________________ 
6. HPE DIAGNOSIS :__________________________________ 
7. INTRATUMOURAL MICRO VESSEL COUNT :______________. 
8. PERITUMOURAL MICRO VESSEL COUNT :________________. 
9. MICROVESSEL GRADE :________________. 
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KEY TO MASTER CHART 
 
LN STATUS - LYMPH NODE STATUS 
MVD - MICROVESSEL DENSITY 
 
